BioAgilytix banner impact of pre-existing immunogenicity agianst aav on gene therapy trials

Impact of Pre-Existing Immunogenicity Against AAV on Gene Therapy Trials

BioAgilytix’s Chief Scientific Officer, Dr. Jim McNally, shares scientific insight focused on the assessment of pre-existing antibodies to the AAV viral capsid and the implications for their impact on the successful dosing (and potential re-dosing) of gene therapy drug candidates.